LAWRENCEVILLE, N.J., March 13, 2014 /PRNewswire/ -- Celsion Corporation (CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2013, and provided an update on its clinical trials of ThermoDox®, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer.
Help employers find you! Check out all the jobs and post your resume.
